Scyllo-Inositol promotes Robust Mutant Huntingtin Protein degradation

Journal of Biological Chemistry

Volumn 289, Issue 6, 2014, Pages 3666-3676

  Lai, Aaron Y ^a   Lan, Cynthia P ^a   Hasan, Salwa ^a   Brown, Mary E ^a   McLaurin, JoAnne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY; HUNTINGTIN; HUNTINGTON DISEASE; LYSOSOMES; NEURODEGENERATIVE DISEASES; PROTEASOME; SCYLLO-INOSITOL;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANIMALS; INOSITOL; LYSOSOMES; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PC12 CELLS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RATS;

EID: 84893673980     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.501635     Document Type: Article

References (57)

1. Ross, C. A., and Tabrizi, S. J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98
2. Vonsattel, J. P. (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 55-69
3. Arrasate, M., and Finkbeiner, S. (2012) Protein aggregates in Huntington's disease. Exp. Neurol. 238, 1-11
4. Sarkar, S., and Rubinsztein, D. C. (2008) Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J. 275, 4263-4270
5. Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K. Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., and Kopito, R. R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature. 448, 704-708
6. Miller, J., Arrasate, M., Shaby, B. A., Mitra, S., Masliah, E., and Finkbeiner, S. (2010) Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J. Neurosci. 30, 10541-10550
7. Miller, J., Arrasate, M., Brooks, E., Libeu, C. P., Legleiter, J., Hatters, D., Curtis, J., Cheung, K., Krishnan, P., Mitra, S., Widjaja, K., Shaby, B. A., Lotz, G. P., Newhouse, Y., Mitchell, E. J., Osmand, A., Gray, M., Thulasiramin, V., Saudou, F., Segal, M., Yang, X. W., Masliah, E., Thompson, L. M., Muchowski, P. J., Weisgraber, K. H., and Finkbeiner, S. (2011) Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 7, 925-934
8. Southwell, A. L., Ko, J., and Patterson, P. H. (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 29, 13589-13602
9. Butler, D. C., and Messer, A. (2011) Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 6, e29199
10. Apostol, B. L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J. E., Gertler, F. B., Hersch, S., Housman, D. E., Marsh, J. L., and Thompson, L. M. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 100, 5950-5955
11. Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W., Waldmeier, P., Housman, D. E., Kazantsev, A., Young, A. B., and Hersch, S. (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 104, 16685-16689
12. Fuentealba, R. A., Marasa, J., Diamond, M. I., Piwnica-Worms, D., and Weihl, C. C. (2012) An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum. Mol. Genet. 21, 664-680
13. van Bebber, F., Paquet, D., Hruscha, A., Schmid, B., and Haass, C. (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol. Dis. 39, 265-271
14. Sontag, E. M., Lotz, G. P., Yang, G., Sontag, C. J., Cummings, B. J., Glabe, C. G., Muchowski, P. J., and Thompson, L. M. (2012) Detection of mutant huntingtin aggregation conformers and modulation of SDS-soluble fibrillar oligomers by small molecules. J. Huntingtons Dis. 1, 127-140
15. Sontag, E. M., Joachimiak, L. A., Tan, Z., Tomlinson, A., Housman, D. E., Glabe, C. G., Potkin, S. G., Frydman, J., and Thompson, L. M. (2013) Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc. Natl. Acad. Sci. U.S.A. 110, 3077-3082
16. Gillis, J., Schipper-Krom, S., Juenemann, K., Gruber, A., Coolen, S., van den Nieuwendijk, R., van Veen, H., Overkleeft, H., Goedhart, J., Kampinga, H. H., and Reits, E. A. (2013) The DNAJB6 and DNAJB8 protein chaperones prevent intracellular aggregation of polyglutamine peptides. J. Biol. Chem. 288, 17225-17237
17. Tashiro, E., Zako, T., Muto, H., Itoo, Y., Sörgjerd, K., Terada, N., Abe, A., Miyazawa, M., Kitamura, A., Kitaura, H., Kubota, H., Maeda, M., Momoi, T., Iguchi-Ariga, S. M., Kinjo, M., and Ariga, H. (2013) Prefoldin protects neuronal cells from polyglutamine toxicity by preventing aggregation formation. J. Biol. Chem. 288, 19958-19972
18. Lu, B., Al-Ramahi, I., Valencia, A., Wang, Q., Berenshteyn, F., Yang, H., Gallego-Flores, T., Ichcho, S., Lacoste, A., Hild, M., Difiglia, M., Botas, J., and Palacino, J. (2013) Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat. Neurosci. 16, 562-570
19. McLaurin, J., Golomb, R., Jurewicz, A., Antel, J. P., and Fraser, P. E. (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid-peptide and inhibit A-induced toxicity. J. Biol. Chem. 275, 18495-18502
20. Lai, A. Y., and McLaurin, J. (2012) Inhibition of amyloid-peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim. Biophys. Acta 1822, 1629-1637
21. Vekrellis, K., Xilouri, M., Emmanouilidou, E., and Stefanis, L. (2009) Inducible overexpression of wild type-synuclein in human neuronal cells leads to caspase-dependent non-Apoptotic death. J. Neurochem. 109, 1348-1362
22. Fenili, D., Weng, Y. Q., Aubert, I., Nitz, M., and McLaurin, J. (2011) Sodium/myo-inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology. PLoS One 6, e24032
23. Larson, M. E., and Lesné, S. E. (2012) Soluble A-oligomer production and toxicity. J. Neurochem. 120, 125-139
24. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810
25. Lichtenberg, M., Mansilla, A., Zecchini, V. R., Fleming, A., and Rubinsztein, D. C. (2011) The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis. 2, e196
26. Khandros, E., Thom, C. S., D'Souza, J., and Weiss, M. J. (2012) Integrated protein quality-control pathways regulate free-globin in murine-thalassemia. Blood 119, 5265-5275
27. Karpuj, M. V., Garren, H., Slunt, H., Price, D. L., Gusella, J., Becher, M. W., and Steinman, L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. U.S.A. 96, 7388-7393
28. Karpuj, M. V., Becher, M. W., Springer, J. E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D., and Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143-149
29. Brundin, P., Melki, R., and Kopito, R. (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301-307
30. Liang, Q., Ouyang, X., Schneider, L., and Zhang, J. (2011) Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol. Neurodegener 6, 37
31. Bhutani, N., Piccirillo, R., Hourez, R., Venkatraman, P., and Goldberg, A. L. (2012) Cathepsins L and Z are critical in degrading polyglutaminecontaining proteins within lysosomes. J. Biol. Chem. 287, 17471-17482
32. Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., and Nixon, R. A. (2010) Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146-1158
33. Kazmi, F., Hensley, T., Pope, C., Funk, R. S., Loewen, G. J., Buckley, D. B., and Parkinson, A. (2013) Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab. Dispos. 41, 897-905
34. Cheung, Z. H., and Ip, N. Y. (2011) Autophagy deregulation in neurodegenerative diseases-recent advances and future perspectives. J. Neurochem. 118, 317-325
35. Klionsky, D. J., Elazar, Z., Seglen, P. O., and Rubinsztein, D. C. (2008) Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy. 4, 849-950
36. Dice, J. F. (1990) Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends Biochem. Sci. 15, 305-309
37. Qi, L., Zhang, X. D., Wu, J. C., Lin, F., Wang, J., DiFiglia, M., and Qin, Z. H. (2012) The role of chaperone-mediated autophagy in huntingtin degradation. PLoS One 7, e46834
38. Wooten, M. W., Hu, X., Babu, J. R., Seibenhener, M. L., Geetha, T., Paine, M. G., and Wooten, M. C. (2006) Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62's role in neurodegenerative disease. J. Biomed. Biotechnol. 2006, 62079
39. Jana, N. R. (2010) Role of the ubiquitin-proteasome system and autophagy in polyglutamine neurodegenerative diseases. Future Neurol. 5, 105-112
40. Wang, J., Wang, C. E., Orr, A., Tydlacka, S., Li, S. H., and Li, X. J. (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 180, 1177-1189
41. Tydlacka, S., Wang, C. E., Wang, X., Li, S., and Li, X. J. (2008) Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J. Neurosci. 28, 13285-13295
42. Hunter, J. M., Lesort, M., and Johnson, G. V. (2007) Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 85, 1774-1788
43. Newton, K., Matsumoto, M. L., Wertz, I. E., Kirkpatrick, D. S., Lill, J. R., Tan, J., Dugger, D., Gordon, N., Sidhu, S. S., Fellouse, F. A., Komuves, L., French, D. M., Ferrando, R. E., Lam, C., Compaan, D., Yu, C., Bosanac, I., Hymowitz, S. G., Kelley, R. F., and Dixit, V. M. (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134, 668-678
44. Li, G., and Pomés, R. (2013) Binding mechanism of inositol stereoisomers to monomers and aggregates of A-(16-22). J. Phys. Chem. B. 117, 6603-6613
45. Li, G., Rauscher, S., Baud, S., and Pomés, R. (2012) Binding of inositol stereoisomers to model amyloidogenic peptides. J. Phys. Chem. B. 116, 1111-1119
46. Török, B., Bag, S., Sarkar, M., Dasgupta, S., and Török, M. (2013) Structural features of small molecule amyloid-self-Assembly inhibitors. Curr. Bioact. Compd. 9, 37-63
47. Ehrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M., Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., Muchowski, P. J., and Wanker, E. E. (2006) Green tea ()-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 15, 2743-2751
48. Jana, N. R., Zemskov, E. A., Wang Gh, and Nukina, N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049-1059
49. Bennett, E. J., Bence, N. F., Jayakumar, R., and Kopito, R. R. (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 17, 351-365
50. Mitra, S., Tsvetkov, A. S., and Finkbeiner, S. (2009) Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease. J. Biol. Chem. 284, 4398-4403
51. Ortega, Z., Díaz-Hernández, M., Maynard, C. J., Hernández, F., Dantuma, N. P., and Lucas, J. J. (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J. Neurosci. 30, 3675-3688
52. Yamamoto, A., Lucas, J. J., and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66
53. Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., Hung, G., Bennett, C. F., and Cleveland, D. W. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 74, 1031-1044
54. Townsend, M., Cleary, J. P., Mehta, T., Hofmeister, J., Lesne, S., O'Hare, E., Walsh, D. M., and Selkoe, D. J. (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-oligomers. Ann. Neurol. 60, 668-676
55. McLaurin, J., Kierstead, M. E., Brown, M. E., Hawkes, C. A., Lambermon, M. H., Phinney, A. L., Darabie, A. A., Cousins, J. E., French, J. E., Lan, M. F., Chen, F., Wong, S. S., Mount, H. T., Fraser, P. E., Westaway, D., and St George-Hyslop, P. (2006) Cyclohexanehexol inhibitors of A-Aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808
56. Fenili, D., Brown, M., Rappaport, R., and McLaurin, J. (2007) Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J. Mol. Med. 85, 603-611
57. Aytan, N., Choi, J. K., Carreras, I., Kowall, N. W., Jenkins, B. G., and Dedeoglu, A. (2013) Combination therapy in a transgenic model of Alzheimer's disease. Exp. Neurol. 250, 228-238